Precisely Controlling the Activation of an Iron-Locked Drug Generator in the Liver Sinusoid to Enhance Barrier Penetration and Reduction of Liver Fibrosis
Journal of the American Chemical Society · 11.12.2024 · 146 (49) · 33784-33803
DOI: 10.1021/jacs.4c11988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 25.11.2024. Verfasst von Quanwei Sun und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230031, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Iron, Deferasirox. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Anhui Provincial Department of Education, Anhui University of Chinese Medicine, National Natural Science Foundation of China.
Abstract (Originalsprache)
Complex physical barriers and the nanomaterial's clearance mechanism in the liver greatly hinder the feasibility of using a conventional liver-targeting nanoplatform to deliver antifibrotic drugs to pathological sites for the treatment of liver fibrosis. Here, a novel drug delivery strategy was designed to overcome drug penetration barriers in a fibrotic liver and cooperated with oral nattokinase (NKase)-mediated antifibrosis therapy as a proof of concept, which relies on the coadministration of a nanosized iron-locked drug generator (named Pro-HAase) and orally absorbed iron chelator deferasirox (DFX). Such a strategy starts from the rapid accumulation of intravenously injected Pro-HAase in the microcapillaries of the fibrotic liver followed by disrupting the polyphenol-iron coordination inside Pro-HAase by DFX, liberating antifibrotic components, including procyanidine (PA) and hyaluronidase (HAase). Attractively, absorption of DFX requires the sequential processes of traversing the intestinal mucosa and targeting the liver, which enable DFX to preferentially disassemble Pro-HAase accumulated in the liver sinusoid rather than in systemic circulation or other organs, thus avoiding the off-target activation of Pro-HAase and depletion of the normal iron pool. The in situ disassembly process decreases the sequestration of Pro-HAase by cells of the mononuclear phagocyte system and promotes gradient-driven permeation of therapeutic components to surrounding liver tissues within 2 h, accompanied by biliary excretion of the inactive iron-DFX complex. As a result, the cooperation of Pro-HAase and DFX not only allows NKase-mediated therapy to completely reverse liver fibrosis but also suppresses the chronic hepatotoxicity of residual liver iron after multiple doses of Pro-HAase. The high spatiotemporal precision, unique barrier-penetration mechanism, and self-detoxification ability of this strategy will inspire the rational design of analogous iron-locked nanosystems to improve the therapeutic outcomes of liver fibrosis or other liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230031, China.
- Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei 230031, China.
- Engineering Technology Research Center of Modernized Pharmaceutics, Anhui Education Department (AUCM),, Hefei 230012, China.
- Anhui Provincial Key Laboratory of Chinese Medicinal Formula, Hefei 230021, China.
ORCID-Profile: Qinghua Wu, Wei Shen, Dengke Yin
Förderung
- Anhui Provincial Department of Education
- Anhui University of Chinese Medicine
- National Natural Science Foundation of China
- Anhui Province
Zitieren
APA
Sun, Q., Yang, W., Song, Z., Lu, H., Shang, W., Li, H., Yang, Z., Gao, W., Li, Y., Xu, Y., Luo, M., Liu, K., Wu, Q., Xuan, Z., Shen, W., Yang, Y., & Yin, D. (2024). Precisely Controlling the Activation of an Iron-Locked Drug Generator in the Liver Sinusoid to Enhance Barrier Penetration and Reduction of Liver Fibrosis. Journal of the American Chemical Society, 146(49), 33784-33803. https://doi.org/10.1021/jacs.4c11988
Vancouver
Sun Q, Yang W, Song Z, Lu H, Shang W, Li H, et al. Precisely Controlling the Activation of an Iron-Locked Drug Generator in the Liver Sinusoid to Enhance Barrier Penetration and Reduction of Liver Fibrosis. Journal of the American Chemical Society. 2024;146(49):33784-33803. doi:10.1021/jacs.4c11988
BibTeX
@article{Sun2024,
author = {Sun, Quanwei and Yang, Wenshuo and Song, Zhengwei and Lu, Huiyu and Shang, Wencui and Li, Huihui and Yang, Zexin and Gao, Wenheng and Li, Yunlong and Xu, Yujing and Luo, Min and Liu, Kang and Wu, Qinghua and Xuan, Zihua and Shen, Wei and Yang, Ye and Yin, Dengke},
title = {Precisely Controlling the Activation of an Iron-Locked Drug Generator in the Liver Sinusoid to Enhance Barrier Penetration and Reduction of Liver Fibrosis},
journal = {Journal of the American Chemical Society},
year = {2024},
volume = {146},
number = {49},
pages = {33784--33803},
doi = {10.1021/jacs.4c11988}
}
EUVIMED